Search - tctmd.com

Displaying 61 - 80 of 537

Sort: Relevancy | Date

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Presenter: Arvind Kumar Venkataramana Raju

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

News Daily News

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Todd Neale

January 29, 2025

News Daily News

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Todd Neale

January 23, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

L.A. McKeown

December 05, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2024

Shelley Wood

December 03, 2024

News Conference News AHA 2024

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Yael L. Maxwell

November 25, 2024

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

L.A. McKeown

November 22, 2024

Advertisement

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Top Heart Failure News of 2024

December 2024 Dispatch for the CV Team

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

TCTMD’s Top 10 Most Popular Stories for November 2024

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content